Clinically, poor sleep quality and low serum β-endorphin correlate with tumor progression and elevated CLOCK/ACSL1 expression, suggesting β-endorphin as a potential therapeutic for SD-associated cancers (Figure 1B) (126). This evidence concerns the gene CLOCK and cancer.